BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 24352048)

  • 1. Large granular lymphocytosis during dasatinib therapy.
    Qiu ZY; Xu W; Li JY
    Cancer Biol Ther; 2014 Mar; 15(3):247-55. PubMed ID: 24352048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy.
    Mustjoki S; Ekblom M; Arstila TP; Dybedal I; Epling-Burnette PK; Guilhot F; Hjorth-Hansen H; Höglund M; Kovanen P; Laurinolli T; Liesveld J; Paquette R; Pinilla-Ibarz J; Rauhala A; Shah N; Simonsson B; Sinisalo M; Steegmann JL; Stenke L; Porkka K
    Leukemia; 2009 Aug; 23(8):1398-405. PubMed ID: 19295545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect?
    Paydas S
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):242-7. PubMed ID: 24210599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia.
    Kim DH; Kamel-Reid S; Chang H; Sutherland R; Jung CW; Kim HJ; Lee JJ; Lipton JH
    Haematologica; 2009 Jan; 94(1):135-9. PubMed ID: 19066329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.
    Kreutzman A; Juvonen V; Kairisto V; Ekblom M; Stenke L; Seggewiss R; Porkka K; Mustjoki S
    Blood; 2010 Aug; 116(5):772-82. PubMed ID: 20413659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion.
    Nagata Y; Ohashi K; Fukuda S; Kamata N; Akiyama H; Sakamaki H
    Int J Hematol; 2010 Jun; 91(5):799-807. PubMed ID: 20405252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical profiles of 7 patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib].
    Hoshino T; Tahara K; Miyawaki K; Hatsumi N; Takada S; Miyawaki S; Sakura T
    Rinsho Ketsueki; 2010 Mar; 51(3):181-8. PubMed ID: 20379112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients.
    Tanaka H; Nakashima S; Usuda M
    Int J Hematol; 2012 Sep; 96(3):308-19. PubMed ID: 22767140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib-induced anti-leukemia cellular immunity through a novel subset of CD57 positive helper/cytotoxic CD4 T cells in chronic myelogenous leukemia patients.
    Watanabe N; Takaku T; Takeda K; Shirane S; Toyota T; Koike M; Noguchi M; Hirano T; Fujiwara H; Komatsu N
    Int J Hematol; 2018 Dec; 108(6):588-597. PubMed ID: 30151740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
    Schiffer CA; Cortes JE; Hochhaus A; Saglio G; le Coutre P; Porkka K; Mustjoki S; Mohamed H; Shah NP
    Cancer; 2016 May; 122(9):1398-407. PubMed ID: 26998677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion.
    Eskazan AE; Eyice D; Kurt EA; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Ferhanoglu B; Aydin Y; Tuzuner N; Ozbek U; Soysal T
    Leuk Res; 2014 Jul; 38(7):781-7. PubMed ID: 24832371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study.
    Iriyama N; Fujisawa S; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
    Am J Hematol; 2015 Sep; 90(9):819-24. PubMed ID: 26103598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study.
    Uchiyama T; Sato N; Narita M; Yamahira A; Iwabuchi M; Furukawa T; Sone H; Takahashi M
    Hematol Oncol; 2013 Sep; 31(3):156-63. PubMed ID: 23108877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
    N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New approved dasatinib regimen available for clinical use.
    Snyder DS
    Expert Rev Anticancer Ther; 2009 Mar; 9(3):285-92. PubMed ID: 19275507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pleural effusions due to dasatinib.
    Brixey AG; Light RW
    Curr Opin Pulm Med; 2010 Jul; 16(4):351-6. PubMed ID: 20375898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The longitudinal analysis of large granular lymphocytosis in patients with Philadelphia chromosome-positive leukemia treated with dasatinib.
    Shimura Y; Horiike S; Tsutsumi Y; Hatsuse M; Okano A; Fuchida S; Kobayashi T; Matsumoto Y; Kuroda J; Kawata-Iida E; Uchiyama H; Uoshima N; Shimazaki C; Kaneko H; Kobayashi Y; Taniwaki M
    Int J Hematol; 2015 Oct; 102(4):426-33. PubMed ID: 26267232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Philadelphia-negative acute lymphoblastic leukemia in a chronic myeloid leukemia patient receiving dasatinib.
    Santos FP; Rodrigues M; Mac-Donald Bley do Nascimento C; Kerbauy FR; Ribeiro AA; Mauro Kutner J; Hamerschlak N
    Cytotherapy; 2010; 12(1):113-5. PubMed ID: 19878083
    [No Abstract]   [Full Text] [Related]  

  • 20. Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events.
    Shayani S
    Ther Drug Monit; 2010 Dec; 32(6):680-7. PubMed ID: 20864900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.